Enzolytics Inc (OTCMKTS:ENZC) continues to see heavy buying interest as the stock is up 155% over the past month. Moreover, the stock is up 235% over the past 6-month.
Market Action
As of 10:15, ENZC stock jumped 9% to $0.3015 with more than 22.96 million shares, compared to its average volume of 3.98 million shares. The stock has moved within a range of $0.2770 – 0.3195 after opening the trade at $0.2833.
Major Trigger:
Enzolytics Announces Its Progress Toward Completion of Clinical Trials for Its Anti-HIV ITV-1 Therapeutic and Plans for Its Distribution Throughout Europe
Key Highlights:
- has concluded definitive plans to advance its previously tested ITV-1 anti-HIV therapeutic to clinical trials and distribution throughout Europe. Completion of these steps will establish its anti-HIV therapy as a significant revenue source for the Company, a meaningful milestone for both human health and Company profitability.
- The Company’s ITV-1 anti-HIV therapeutic earlier progressed toward certification under the Bulgarian Drug Agency (BDA) but that process was interrupted before completion. However, in that process, significant positive clinical trial results in patients were documented. These positive results give the Company total confidence that the now planned clinical trials under the European Medicines Agency (EMA) will likewise be successful.
- The steps now in place to accomplish the Company’s goal of bringing its anti-HIV ITV-1 therapeutic to patients are:
- The Company has formed International Medical Partners Ltd. (IMPL) in partnership with European partners.
- IMPL is owned equally by the Company and its partners and has the licenses to distribute the ITV-1 therapeutic in the 27 European countries covered by the European Medical Agency plus Russia, Georgia, Ukraine, Moldova, Belarus, Armenia, Azerbaijan, Kazakhstan, Uzbekistan, Turkmenistan, Kyrgyzstan, Tajikistan, Estonia, Latvia and Lithuania.
 Extends Rally){kind=link}